<![CDATA[Ferritin is a key mediator of immune dysregulation through its direct pro-inflammatory effects, which contribute to inflammatory cytokine storms and tissue damage. This study aims to analyze ferritin roles in distinguish the severity and predict the outcome of COVID-19 patients. An observational analytic study, using a cross-sectional design, enrolled 142 patients which subsequently divided into a non-severe (mild to moderate cases) and a severe (severe to critically ill cases) group. The levels of ferritin was examined using Enzyme Immunoassay Test Kit on the first day patients was hospitalized. Mann Whitney test was used to analyze the correlation between ferritin levels with severity and outcome of COVID-19 patients. The median of ferritin level was higher in the severe group (1532.1 ng/ml, SD= 1715.552) compared to non-severe group (413.3 ng/ml, SD= 459.804) with a statistically significant difference (p< 0.001), cut off point of 865.1 ng/ml, sensitivity of 86.96% (95% CI: 76.68%–93.86%), and specificity of 87.67% (95% CI: 77.88%–94.20%). Ferritin levels were also higher in non-survivors (1496.55 ng/ml, SD = 1798.677) than in survivors (662.05 ng/ml, SD = 1293.026), with a significant difference (p < 0.001), cut off point of 1032.85 ng/ml, sensitivity of 63.33% (95% CI: 43.86% to 80.07%), and specificity of 63.39% (95% CI: 53.76% to 72.29%). This results showed that ferritin levels may not good enough to predict the outcomes, with Contingency coefficient of 0.244 that showed a very weak correlation. The baseline ferritin levels at admission was closely related to the severity of COVID-19, thus it may be considered a potential biomarker for assessing disease severity. However, ferritin levels appear to be insufficiently accurate for predicting clinical outcomes in COVID-19 patients. ]]>
